KCNQ channel openers reverse depressive symptoms via an active resilience mechanism

Allyson K. Friedman, Barbara Juarez, Stacy M. Ku, Hongxing Zhang, Rhodora C. Calizo, Jessica J. Walsh, Dipesh Chaudhury, Song Zhang, Angel Hawkins, David M. Dietz, James W. Murrough, Maria Ribadeneira, Erik H. Wong, Rachael L. Neve, Ming Hu Han

Research output: Contribution to journalArticle

Abstract

Less than half of patients suffering from major depressive disorder, a leading cause of disability worldwide, achieve remission with current antidepressants, making it imperative to develop more effective treatment. A new therapeutic direction is emerging from the increased understanding of natural resilience as an active stress-coping process. It is known that potassium (K+) channels in the ventral tegmental area (VTA) are an active mediator of resilience. However, no druggable targets have been identified to potentiate active resilience mechanisms. In the chronic social defeat stress model of depression, we report that KCNQ-type K+ channel openers, including FDA-approved drug retigabine (ezogabine), show antidepressant efficacy. We demonstrate that overexpression of KCNQ channels in the VTA dopaminergic neurons and either local infusion or systemic administration of retigabine normalized neuronal hyperactivity and depressive behaviours. These findings identify KCNQ as a target for conceptually novel antidepressants that function through the potentiation of active resilience mechanisms.

Original languageEnglish (US)
Article number11671
JournalNature Communications
Volume7
DOIs
StatePublished - May 24 2016

Fingerprint

resilience
Antidepressive Agents
Ventral Tegmental Area
Depression
Dopaminergic Neurons
Potassium Channels
Major Depressive Disorder
disabilities
Neurons
Potassium
neurons
emerging
potassium
drugs
disorders
Therapeutics
Pharmaceutical Preparations
ezogabine
causes

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Friedman, A. K., Juarez, B., Ku, S. M., Zhang, H., Calizo, R. C., Walsh, J. J., ... Han, M. H. (2016). KCNQ channel openers reverse depressive symptoms via an active resilience mechanism. Nature Communications, 7, [11671]. https://doi.org/10.1038/ncomms11671

KCNQ channel openers reverse depressive symptoms via an active resilience mechanism. / Friedman, Allyson K.; Juarez, Barbara; Ku, Stacy M.; Zhang, Hongxing; Calizo, Rhodora C.; Walsh, Jessica J.; Chaudhury, Dipesh; Zhang, Song; Hawkins, Angel; Dietz, David M.; Murrough, James W.; Ribadeneira, Maria; Wong, Erik H.; Neve, Rachael L.; Han, Ming Hu.

In: Nature Communications, Vol. 7, 11671, 24.05.2016.

Research output: Contribution to journalArticle

Friedman, AK, Juarez, B, Ku, SM, Zhang, H, Calizo, RC, Walsh, JJ, Chaudhury, D, Zhang, S, Hawkins, A, Dietz, DM, Murrough, JW, Ribadeneira, M, Wong, EH, Neve, RL & Han, MH 2016, 'KCNQ channel openers reverse depressive symptoms via an active resilience mechanism', Nature Communications, vol. 7, 11671. https://doi.org/10.1038/ncomms11671
Friedman, Allyson K. ; Juarez, Barbara ; Ku, Stacy M. ; Zhang, Hongxing ; Calizo, Rhodora C. ; Walsh, Jessica J. ; Chaudhury, Dipesh ; Zhang, Song ; Hawkins, Angel ; Dietz, David M. ; Murrough, James W. ; Ribadeneira, Maria ; Wong, Erik H. ; Neve, Rachael L. ; Han, Ming Hu. / KCNQ channel openers reverse depressive symptoms via an active resilience mechanism. In: Nature Communications. 2016 ; Vol. 7.
@article{f449b576a8b347d78b65d282fe30cdda,
title = "KCNQ channel openers reverse depressive symptoms via an active resilience mechanism",
abstract = "Less than half of patients suffering from major depressive disorder, a leading cause of disability worldwide, achieve remission with current antidepressants, making it imperative to develop more effective treatment. A new therapeutic direction is emerging from the increased understanding of natural resilience as an active stress-coping process. It is known that potassium (K+) channels in the ventral tegmental area (VTA) are an active mediator of resilience. However, no druggable targets have been identified to potentiate active resilience mechanisms. In the chronic social defeat stress model of depression, we report that KCNQ-type K+ channel openers, including FDA-approved drug retigabine (ezogabine), show antidepressant efficacy. We demonstrate that overexpression of KCNQ channels in the VTA dopaminergic neurons and either local infusion or systemic administration of retigabine normalized neuronal hyperactivity and depressive behaviours. These findings identify KCNQ as a target for conceptually novel antidepressants that function through the potentiation of active resilience mechanisms.",
author = "Friedman, {Allyson K.} and Barbara Juarez and Ku, {Stacy M.} and Hongxing Zhang and Calizo, {Rhodora C.} and Walsh, {Jessica J.} and Dipesh Chaudhury and Song Zhang and Angel Hawkins and Dietz, {David M.} and Murrough, {James W.} and Maria Ribadeneira and Wong, {Erik H.} and Neve, {Rachael L.} and Han, {Ming Hu}",
year = "2016",
month = "5",
day = "24",
doi = "10.1038/ncomms11671",
language = "English (US)",
volume = "7",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - KCNQ channel openers reverse depressive symptoms via an active resilience mechanism

AU - Friedman, Allyson K.

AU - Juarez, Barbara

AU - Ku, Stacy M.

AU - Zhang, Hongxing

AU - Calizo, Rhodora C.

AU - Walsh, Jessica J.

AU - Chaudhury, Dipesh

AU - Zhang, Song

AU - Hawkins, Angel

AU - Dietz, David M.

AU - Murrough, James W.

AU - Ribadeneira, Maria

AU - Wong, Erik H.

AU - Neve, Rachael L.

AU - Han, Ming Hu

PY - 2016/5/24

Y1 - 2016/5/24

N2 - Less than half of patients suffering from major depressive disorder, a leading cause of disability worldwide, achieve remission with current antidepressants, making it imperative to develop more effective treatment. A new therapeutic direction is emerging from the increased understanding of natural resilience as an active stress-coping process. It is known that potassium (K+) channels in the ventral tegmental area (VTA) are an active mediator of resilience. However, no druggable targets have been identified to potentiate active resilience mechanisms. In the chronic social defeat stress model of depression, we report that KCNQ-type K+ channel openers, including FDA-approved drug retigabine (ezogabine), show antidepressant efficacy. We demonstrate that overexpression of KCNQ channels in the VTA dopaminergic neurons and either local infusion or systemic administration of retigabine normalized neuronal hyperactivity and depressive behaviours. These findings identify KCNQ as a target for conceptually novel antidepressants that function through the potentiation of active resilience mechanisms.

AB - Less than half of patients suffering from major depressive disorder, a leading cause of disability worldwide, achieve remission with current antidepressants, making it imperative to develop more effective treatment. A new therapeutic direction is emerging from the increased understanding of natural resilience as an active stress-coping process. It is known that potassium (K+) channels in the ventral tegmental area (VTA) are an active mediator of resilience. However, no druggable targets have been identified to potentiate active resilience mechanisms. In the chronic social defeat stress model of depression, we report that KCNQ-type K+ channel openers, including FDA-approved drug retigabine (ezogabine), show antidepressant efficacy. We demonstrate that overexpression of KCNQ channels in the VTA dopaminergic neurons and either local infusion or systemic administration of retigabine normalized neuronal hyperactivity and depressive behaviours. These findings identify KCNQ as a target for conceptually novel antidepressants that function through the potentiation of active resilience mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=84969922360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969922360&partnerID=8YFLogxK

U2 - 10.1038/ncomms11671

DO - 10.1038/ncomms11671

M3 - Article

VL - 7

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 11671

ER -